Bio Crab Apple

Dosage for Malus Pumila Flower is highly individualized and must be determined by an allergy specialist based on the patient's clinical history and sensitivity levels. There is no 'standard' dose for non-standardized extracts.

Diagnostic Dosing

• Skin Prick Test (SPT): Typically, one drop of the 1:10 or 1:20 w/v extract is applied to the skin, followed by a puncture. A positive control (histamine) and negative control (saline) are used for comparison.
• Intradermal Test: If the SPT is negative but suspicion remains high, 0.02 mL of a 1:1000 to 1:100 v/v dilution may be injected into the dermis.

Immunotherapy Dosing (If applicable)

• Build-up Phase: Starts with a very low dose (e.g., 0.05 mL of a 1:100,000 dilution) and increases weekly or bi-weekly until a maintenance dose is reached.
• Maintenance Phase: The highest dose tolerated by the patient, often administered every 2 to 4 weeks for a period of 3 to 5 years.

Malus Pumila Flower is not typically recommended for infants under the age of 2, as the immune system is still developing and skin reactivity may be inconsistent. For children over 2, the diagnostic procedure is identical to adults, though the number of tests performed in one session may be limited to reduce discomfort. Immunotherapy in children requires careful monitoring of growth and potential systemic reactions.

Renal Impairment

No specific dose adjustments are provided in the manufacturer's labeling for renal impairment. However, since the clearance of inflammatory mediators is essential, patients with end-stage renal disease should be monitored closely for prolonged reactions.

Hepatic Impairment

No dose adjustments are required for hepatic impairment, as the liver does not play a primary role in the metabolism of protein-based allergenic extracts.

Elderly Patients

In elderly patients, skin reactivity may be diminished (reduced wheal and flare response). Clinicians should consider this 'false negative' risk. Additionally, elderly patients are more likely to be on beta-blockers, which is a significant precaution for any allergenic extract use.

This medication is NEVER self-administered at home for diagnostic purposes. It must be administered in a clinical setting.

• Administration Site: Usually the volar surface of the forearm or the upper back.
• Preparation: The skin should be cleaned with alcohol and allowed to dry completely.
• Observation: Patients must remain in the medical office for at least 30 minutes following any injection or intensive skin testing to monitor for systemic reactions.
• Storage: Extracts must be kept refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. Freezing can denature the proteins, rendering the extract ineffective or potentially dangerous.

In the context of immunotherapy, a missed dose requires a 'step-back' in dosage. If a dose is missed by more than one week, the allergist may repeat the previous dose. If missed by several weeks, the dose may need to be reduced significantly to prevent a systemic reaction during the 're-introduction' phase.

An overdose of Malus Pumila Flower extract (either too high a concentration in testing or an incorrect volume in therapy) can lead to a massive release of histamine.

Signs of Overdose/Systemic Reaction:

• Generalized hives (urticaria)
• Swelling of the throat or tongue (angioedema)
• Wheezing or difficulty breathing
• Rapid drop in blood pressure (hypotension)
• Loss of consciousness

Emergency Measures:

Immediate administration of intramuscular epinephrine (0.3mg for adults) is the primary treatment. Supportive care with oxygen, IV fluids, and antihistamines should follow in an emergency department.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

Most patients undergoing testing or treatment with Malus Pumila Flower will experience localized reactions. These are generally considered expected pharmacological effects of the extract.

• Localized Wheal and Flare: A raised, itchy bump at the site of testing. This typically peaks at 15-20 minutes and resolves within 1-2 hours.
• Pruritus (Itching): Intense itching at the site of administration.
• Erythema (Redness): Redness surrounding the test site that may spread slightly.
• Local Swelling: In immunotherapy, the injection site may swell (up to the size of a half-dollar). This is common and usually managed with cold compresses.

• Delayed Local Reactions: Swelling and redness that appear 6 to 24 hours after administration. These can be uncomfortable but are rarely dangerous.
• Fatigue: Some patients report feeling unusually tired for a few hours following an immunotherapy injection.
• Headache: Mild tension-type headaches have been reported following allergen exposure.

• Generalized Urticaria: Hives appearing on parts of the body far from the injection or test site.
• Lymphadenopathy: Swelling of the lymph nodes near the site of injection.
• Granuloma: A small, firm bump under the skin at the injection site caused by a chronic inflammatory response to the glycerin or the proteins.

> Warning: Stop taking Malus Pumila Flower and call your doctor immediately if you experience any of these symptoms of anaphylaxis.

• Respiratory Distress: Shortness of breath, chest tightness, or a high-pitched whistling sound when breathing (stridor).
• Upper Airway Obstruction: Feeling of a 'lump in the throat,' hoarseness, or difficulty swallowing.
• Cardiovascular Collapse: Dizziness, fainting, rapid or weak pulse, and a sudden drop in blood pressure.
• Gastrointestinal Distress: Severe abdominal cramping, vomiting, or diarrhea occurring immediately after administration.
• Angioedema: Significant swelling of the lips, face, or tongue that may obstruct the airway.

Prolonged use of allergenic extracts in immunotherapy is generally well-tolerated. However, some patients may develop a persistent 'late-phase' inflammatory response at the injection site. There is no evidence that long-term use of Malus Pumila Flower extract leads to autoimmune disease or malignancy.

While Malus Pumila Flower specifically may not have a unique black box warning, the FDA requires a Class Black Box Warning for all allergenic extracts.

Summary of Warning:

• Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylaxis.
• They should only be administered by healthcare professionals prepared to manage such reactions.
• Patients with unstable or severe asthma are at increased risk for fatal outcomes.
• Extracts may not be suitable for patients taking beta-blockers, as they may be unresponsive to epinephrine.

Report any unusual symptoms to your healthcare provider.

Malus Pumila Flower extract is a potent biological substance. It must only be used by clinicians who are experts in the diagnosis and treatment of allergic diseases. Patients must be screened for current health status before every administration. For example, if a patient is currently experiencing an asthma flare or a severe viral infection, the administration of the extract should be postponed to avoid priming the immune system for a systemic reaction.

No specific individual black box warning exists for Malus Pumila Flower, but it falls under the general FDA mandate for allergenic extracts: "WARNING: Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylaxis. Patients must be observed for at least 30 minutes. Epinephrine must be available."

• Anaphylaxis Risk: This is the most significant risk. Anaphylaxis can occur even in patients who have previously tolerated the extract without issue. Factors that increase risk include vigorous exercise after the injection, hot showers, or high stress.
• Asthma: Patients with uncontrolled asthma (FEV1 < 80% of predicted) should not receive allergenic extracts, as they are at the highest risk for fatal bronchospasm during a systemic reaction.
• Cardiovascular Disease: Patients with pre-existing heart conditions may not tolerate the physiological stress of a systemic reaction or the side effects of the epinephrine used to treat it.
• Beta-Blocker Use: Beta-blockers (medications for blood pressure or glaucoma) can block the effects of epinephrine, making it difficult to treat an allergic reaction if one occurs.

• Observation Period: A mandatory 30-minute wait in the clinic after administration.
• Peak Flow Meter: For asthmatic patients, a peak flow reading may be taken before the injection to ensure respiratory stability.
• Skin Site Assessment: Measurement of the wheal and flare diameter during diagnostic testing.

Malus Pumila Flower does not typically cause sedation. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive or operate machinery until they are fully recovered and cleared by a physician.

Alcohol consumption should be avoided on the day of testing or immunotherapy. Alcohol can cause vasodilation (widening of blood vessels), which may increase the rate of allergen absorption and potentially trigger a more severe reaction.

If a patient experiences a Grade 3 or 4 systemic reaction (anaphylaxis), the clinician will perform a risk-benefit analysis. In many cases, the extract is discontinued, or the dose is drastically reduced and the build-up phase restarted with extreme caution.

> Important: Discuss all your medical conditions with your healthcare provider before starting Malus Pumila Flower.

• Beta-Blockers (e.g., Propranolol, Atenolol): These are often considered a relative or absolute contraindication for allergenic extract use. They interfere with the beta-adrenergic receptors that epinephrine targets. If a patient on a beta-blocker has anaphylaxis, the standard dose of epinephrine may fail to reverse the airway obstruction or hypotension.

• ACE Inhibitors (e.g., Lisinopril): Some studies suggest that ACE inhibitors may increase the severity of anaphylactic reactions or interfere with the body's natural compensatory mechanisms during an allergic event.
• MAO Inhibitors (e.g., Phenelzine): These can potentiate the effects of epinephrine, leading to a dangerous spike in blood pressure if an emergency occurs.
• Tricyclic Antidepressants (e.g., Amitriptyline): Similar to MAOIs, these can increase the cardiovascular sensitivity to epinephrine.

• Antihistamines (e.g., Cetirizine, Loratadine): These must be stopped 3 to 7 days before diagnostic testing. Antihistamines block the H1 receptors in the skin, which prevents the 'wheal and flare' from forming, leading to a false-negative result. They do not typically interfere with the efficacy of long-term immunotherapy.
• H2 Blockers (e.g., Famotidine): These can also modestly suppress skin test reactivity and should be discontinued prior to testing.

• Cross-Reactive Foods: Patients sensitive to Malus Pumila Flower may also react to raw apples, pears, peaches, and cherries. Consuming these foods immediately before or after a clinical dose of the extract may increase the total 'allergen load' and trigger a reaction.

• St. John's Wort: May affect the metabolism of various medications, though its direct interaction with allergenic proteins is unstudied.
• Astragalus/Echinacea: These immune-stimulating herbs could theoretically interfere with the desensitization process of immunotherapy, though clinical data is lacking.

• Skin Tests: As mentioned, antihistamines and certain antidepressants can cause false negatives.
• Serum IgE: Treatment with Malus Pumila Flower extracts will cause a transient rise in specific IgE levels, followed by a long-term decline. This is a normal part of the therapy and not a sign of 'worsening' allergy.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

• Severe Uncontrolled Asthma: Patients with a forced expiratory volume in 1 second (FEV1) of less than 80% of their predicted value or those with frequent exacerbations. The risk of fatal bronchospasm during a reaction is unacceptably high.
• Recent Myocardial Infarction (Heart Attack): Within the last 3-6 months. The heart may not be able to handle the stress of anaphylaxis or the administration of emergency epinephrine.
• Hypersensitivity to Excipients: Patients with a known severe allergy to glycerin or phenol (preservatives used in the extract) should not receive this product.

• Pregnancy: While not directly teratogenic, the risk of anaphylaxis-induced fetal hypoxia (lack of oxygen to the baby) is significant. Most allergists will not start a new course of immunotherapy during pregnancy but may continue a maintenance dose if it is well-tolerated.
• Autoimmune Disorders: Patients with active systemic lupus erythematosus (SLE) or rheumatoid arthritis may experience a flare-up of their condition if the immune system is stimulated with allergenic extracts.
• Severe Atopic Dermatitis: If the skin is too inflamed, accurate skin testing may be impossible (the 'Red Dermographism' effect).

Patients allergic to Malus Pumila Flower are highly likely to be cross-sensitive to other members of the Rosaceae family (including Malus domestica fruit, Prunus persica/Peach, and Prunus avium/Cherry). There is also a very high rate of cross-sensitivity with Birch Pollen (Betula verrucosa) due to the structural similarity between the Mal d 1 and Bet v 1 proteins.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Malus Pumila Flower.

FDA Category C: Animal reproduction studies have not been conducted with Malus Pumila Flower extract. It is also not known whether the extract can cause fetal harm when administered to a pregnant woman. The primary concern is not the extract itself, but the potential for a systemic reaction (anaphylaxis) in the mother. Anaphylaxis causes a sudden drop in maternal blood pressure, which can lead to placental insufficiency and fetal distress.

Clinical Guidance: Immunotherapy build-up should be suspended during pregnancy. Maintenance therapy may be continued if the benefit of controlling severe allergic symptoms outweighs the risk of a reaction.

It is not known whether the allergenic components of Malus Pumila Flower are excreted in human milk. However, because these are large proteins that are likely digested in the infant's gut, the risk to the nursing child is considered low. The decision to continue therapy while breastfeeding should be made based on the mother's clinical need.

Safety and effectiveness in children under the age of 2 have not been established. In older children, Malus Pumila Flower is used for diagnosis, but clinicians must be mindful of the psychological impact of skin testing and the risk of systemic reactions. Children with a history of severe asthma require particularly close monitoring.

Clinical studies of Malus Pumila Flower did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, older adults often have comorbidities (like heart disease) or are taking medications (like beta-blockers) that make the use of allergenic extracts riskier. Dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range.

There are no specific guidelines for Malus Pumila Flower in renal impairment. Since the proteins are degraded into amino acids, significant accumulation is unlikely. However, the patient's ability to handle the physiological stress of a potential reaction should be assessed.

Hepatic impairment does not significantly affect the processing of allergenic extracts. No specific dose adjustments are required for patients with liver disease.

> Important: Special populations require individualized medical assessment.

Malus Pumila Flower extract acts as a specific antigen that interacts with the adaptive immune system. The primary active components are proteins, most notably the Mal d 1 allergen (a PR-10 protein) and potentially Mal d 3 (a lipid transfer protein).

1. 1Recognition: Upon administration, these proteins are taken up by dendritic cells (antigen-presenting cells).
2. 2Processing: The dendritic cells break the proteins into peptides and present them on MHC Class II molecules to T-cell receptors.
3. 3Response: In an allergic individual, this triggers a Th2 response. In immunotherapy, the goal is to induce 'T-cell anergy' or the production of Regulatory T-cells (Tregs) that secrete IL-10 and TGF-beta, which suppress allergic inflammation.

• Onset of Action (Testing): 15 to 20 minutes for a wheal and flare response.
• Onset of Action (Therapy): 6 months to 1 year of consistent injections are usually required before a reduction in clinical symptoms is observed.
• Duration of Effect: A successful course of immunotherapy can provide desensitization that lasts for 3 to 5 years or longer after treatment stops.

| Parameter | Value |

|---|---|

| Bioavailability | Low (Local/Subcutaneous) |

| Protein Binding | N/A (Protein-based) |

| Half-life | Hours (Allergen) / Years (Immune Memory) |

| Tmax | 15-30 minutes (Local absorption) |

| Metabolism | Proteolysis by tissue enzymes |

| Excretion | Renal (as peptide fragments) |

• Molecular Formula: Complex mixture of proteins (C, H, N, O, S).
• Molecular Weight: Ranges from 10 kDa to 70 kDa for major allergens.
• Solubility: Highly soluble in aqueous solutions and 50% glycerin.
• Structure: Globular proteins with specific epitopes (binding sites) for IgE antibodies.

Malus Pumila Flower is classified as a Non-Standardized Food Allergenic Extract. It belongs to the broader therapeutic category of Biologicals / Immunomodulators. It is related to other fruit-based extracts like Prunus persica (Peach) and Pyrus communis (Pear) extracts.